Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant

Completed

• Conditions: Hepatocellular Carcinoma Recurrent; Hepatocellular Carcinoma
• Interventions: Drug: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use

• Registration Number: NCT06233708
• Lead Sponsor: Asan Medical Center

Brief Summary

The goal of this observational study is to investigate the effect of non-selective beta-blocker (NSBB) on the recurrence of hepatocellular carcinoma (HCC) following liver transplantation in patients who underwent liver transplantation (LT) for treating hepatocellular carcinoma.

The main question\[s\] it aims to answer are:

* Is the usage of non-selective beta-blocker associated with decreased recurrence of hepatocellular carcinoma following liver transplantation?

* Is the usage of non-selective beta-blocker associated with all-cause mortality following liver transplantation?

Researchers will compare the NSBB group, including patients who received non-selective beta-blocker therapy for at least 30 consecutive days within 3 months prior to liver transplantation more than 30 days prior, with the control group to to see if non-selective beta-blocker treatment is associated with decreased recurrence of hepatocellular carcinoma following liver transplantation.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-01
• Primary Completion: 2022-05-31
• Study Completion: 2022-05-31
• Status Verified: 2024-01
• Study First Submitted: 2024-01-19
• Study First Submitted QC: 2024-01-28
• Last Update Submitted: 2024-01-28
• Study First Posted: 2024-01-31
• Last Update Posted: 2024-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2092

Inclusion Criteria

• Adult patients
• Underwent liver transplantation for treating hepatocellular carcinoma
• Between Jan. 2008 - May. 2022

Exclusion Criteria

• Pediatric patients (Age under 18 years)
• Re-transplantation
• Multi-organ transplantation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
NSBB group	Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use	The NSBB group was defined as those who received NSBBs for at least 30 consecutive days within the 3 months prior to LT.

Primary Outcome Measures

Name	Time	Method
Kaplan-Meier survival analysis of HCC recurrence at 5-year follow-up	Baseline and 5-year follow-up	HCC recurrence, which was diagnosed based on pathological or radiographic evidence of new lesions consistent with HCC, and recurrence-free survival was collected and compared using Kaplan-Meier survival analysis.
Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up	Baseline and 5-year follow-up	Multivariate Cox regression analysis was performed to identify the risk factors for HCC recurrence.

Secondary Outcome Measures

Name	Time	Method
Kaplan-Meier survival analysis of overall survival at 5-year follow-up	Baseline and 5-year follow-up	Overall survival was collected and compared using Kaplan-Meier survival analysis.
Multivariate Cox regression analysis of overall survival at 5-year follow-up	Baseline and 5-year follow-up	Multivariate Cox regression analysis was performed to identify the risk factors for overall mortality.